ALIVUS LIFE SCIENCES SHARE PRICE

Alivus Life Sciences Limited was initially established as `Zorg Laboratories Private Limited`, on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited` and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to `Alivus Life Sciences Limited` on January 20, 2025. Nirma Limited is a Subsidiary of the Company. The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKline`s (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL. The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023. The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021. FY24 ushered in a new chapter with Nirma Limited, a diversified conglomerate with interests in consumer products, cement, chemicals, and pharmaceuticals, acquiring a majority stake in GLS. In FY 2023-24, 75% of the equity stake of the Company was transferred by the promoter, Glenmark Pharmaceuticals Limited (GPL) to Nirma Limited on March 6, 2024. Resulting this, there was a change in ownership status via share purchase agreement, and Nirma became the new promoter of the Company. A separate facility for Ezetimibe was commissioned and became operational at Ankleshwar in FY25. Two independent modules were commissioned in FY 2025 and made operational at Dahej.

Alivus Life Sciences share price as on 05 Dec 2025 is Rs. 876.75. Over the past 6 months, the Alivus Life Sciences share price has decreased by 14.34% and in the last one year, it has decreased by 19.96%. The 52-week low for Alivus Life Sciences share price was Rs. 850 and 52-week high was Rs. 1251.

Alivus Life Sciences Limited was initially established as `Zorg Laboratories Private Limited`, on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited` and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to `Alivus Life Sciences Limited` on January 20, 2025. Nirma Limited is a Subsidiary of the Company. The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKline`s (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL. The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023. The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021. FY24 ushered in a new chapter with Nirma Limited, a diversified conglomerate with interests in consumer products, cement, chemicals, and pharmaceuticals, acquiring a majority stake in GLS. In FY 2023-24, 75% of the equity stake of the Company was transferred by the promoter, Glenmark Pharmaceuticals Limited (GPL) to Nirma Limited on March 6, 2024. Resulting this, there was a change in ownership status via share purchase agreement, and Nirma became the new promoter of the Company. A separate facility for Ezetimibe was commissioned and became operational at Ankleshwar in FY25. Two independent modules were commissioned in FY 2025 and made operational at Dahej.

Alivus Life Sciences share price as on 05 Dec 2025 is Rs. 876.75. Over the past 6 months, the Alivus Life Sciences share price has decreased by 14.34% and in the last one year, it has decreased by 19.96%. The 52-week low for Alivus Life Sciences share price was Rs. 850 and 52-week high was Rs. 1251.